Arvinas, Inc. (ARVN) announced positive updates from multiple clinical trials in oncology and neurology, advancing its pipeline with measurable progress in patient enrollment, safety data, and early efficacy signals. The developments are expected to strengthen the company’s position in targeted protein degradation therapeutics.
- ARVN achieved 189-patient enrollment in Phase 2 trial of ARV-471 for breast cancer, with a 45% objective response rate.
- ARV-110 demonstrated 32% PSA decline in 67% of mCRPC patients in Phase 1b/2a study.
- ARV-375 trial in Parkinson’s disease met primary endpoints for safety and target engagement in CSF.
- Three new trials initiated in 2026, including combination therapy and resistance-focused studies.
- ARVN stock rose 12% post-announcement, outperforming XLV (+3.2%) and IBB (+4.1%).
Arvinas, Inc. (ARVN) has reported substantial advancements in its clinical development programs, highlighting progress in both oncology and neurology indications. In its Phase 2 trial of ARV-471 for ER-positive, HER2-negative breast cancer, the company achieved enrollment of 189 patients, exceeding initial targets, with preliminary data showing a 45% objective response rate in heavily pretreated patients. The trial continues to assess safety and pharmacodynamic markers, with full data expected by Q3 2026. In neurology, the Phase 1b/2a study of ARV-110 in metastatic castration-resistant prostate cancer (mCRPC) demonstrated a 32% decline in PSA levels in 67% of evaluable patients, supporting continued development in the oncology space. Additionally, a separate Phase 1 trial of ARV-375, a novel degrader targeting alpha-synuclein, enrolled 42 patients with early-stage Parkinson’s disease, meeting primary endpoints for tolerability and target engagement in cerebrospinal fluid samples. These milestones reflect Arvinas’ expanding pipeline across high-unmet-need therapeutic areas. The company has initiated three new trials in 2026, including a combination study of ARV-471 with CDK4/6 inhibitors in advanced breast cancer and a trial evaluating ARV-110 in patients with treatment-emergent resistance. The positive clinical updates have contributed to a 12% rise in ARVN’s stock price over the past two weeks, outpacing the broader healthcare sector benchmark (XLV) and the Nasdaq Biotechnology Index (IBB), which rose 3.2% and 4.1%, respectively. Analysts note the data strengthens Arvinas' potential to become a leader in targeted protein degradation, attracting interest from institutional investors and biotech-focused funds.